Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fansheng Ran

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
European Journal of Medicinal Chemistry|April 30, 2021
Overview of piperlongumine analogues and their therapeutic potentialPeng Zhu, Jianqiang Qian, Zhongyuan Xu, et al.
European Journal of Medicinal Chemistry|November 18, 2022
Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effectsFansheng Ran, Xudong Xie, Qilin Wu, et al.
Bioorganic Chemistry|March 29, 2023
Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemiaFansheng Ran, Yun Liu, Jian Zhu, et al.
European Journal of Medicinal Chemistry|January 14, 2026
Discovery of novel aminopyrimidine-hydroxamate derivatives as dual FLT3/HDAC inhibitors: Design, synthesis, and anti-hematologic malignancy evaluationFansheng Ran, Rong Cao, Yifan Ma, et al.
Journal of Medicinal Chemistry|July 25, 2022
Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination ChemotherapyJianqiang Qian, Zhongyuan Xu, Chi Meng, et al.
Journal of Natural Products|November 22, 2021
A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular CarcinomaJianqiang Qian, Zhongyuan Xu, Peng Zhu, et al.
Theranostics|April 11, 2022
TME-targeting theranostic agent uses NIR tracking for tumor diagnosis and surgical resection and acts as chemotherapeutic showing enhanced efficiency and minimal toxicityZhongyuan Xu, Jianqiang Qian, Chi Meng, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
European Journal of Medicinal Chemistry|April 30, 2021
Overview of piperlongumine analogues and their therapeutic potentialPeng Zhu, Jianqiang Qian, Zhongyuan Xu, et al.
European Journal of Medicinal Chemistry|November 18, 2022
Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effectsFansheng Ran, Xudong Xie, Qilin Wu, et al.
Bioorganic Chemistry|March 29, 2023
Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemiaFansheng Ran, Yun Liu, Jian Zhu, et al.
European Journal of Medicinal Chemistry|January 14, 2026
Discovery of novel aminopyrimidine-hydroxamate derivatives as dual FLT3/HDAC inhibitors: Design, synthesis, and anti-hematologic malignancy evaluationFansheng Ran, Rong Cao, Yifan Ma, et al.
Journal of Medicinal Chemistry|July 25, 2022
Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination ChemotherapyJianqiang Qian, Zhongyuan Xu, Chi Meng, et al.
Journal of Natural Products|November 22, 2021
A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular CarcinomaJianqiang Qian, Zhongyuan Xu, Peng Zhu, et al.
Theranostics|April 11, 2022
TME-targeting theranostic agent uses NIR tracking for tumor diagnosis and surgical resection and acts as chemotherapeutic showing enhanced efficiency and minimal toxicityZhongyuan Xu, Jianqiang Qian, Chi Meng, et al.
Pageof 2